Parallel Advisors, LLC - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 221 filers reported holding BRIDGEBIO PHARMA INC in Q1 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.4%.

Quarter-by-quarter ownership
Parallel Advisors, LLC ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2023$738
+53.1%
280.0%0.00%
Q2 2023$482
+3.9%
280.0%0.00%
Q1 2023$464
+117.8%
280.0%0.00%
Q4 2022$21328
-17.6%
0.00%
Q2 2022$0
-100.0%
34
-71.9%
0.00%
Q4 2021$2,000
-91.3%
121
-75.2%
0.00%
-100.0%
Q3 2021$23,000
-23.3%
4880.0%0.00%0.0%
Q2 2021$30,000
-53.1%
488
-52.8%
0.00%
-66.7%
Q1 2021$64,0001,0330.00%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q1 2023
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$160,016,45665.94%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$819,077,80528.79%
Cormorant Asset Management, LP 4,662,530$122,950,9167.17%
Frazier Life Sciences Management, L.P. 2,725,949$71,883,2754.77%
Octagon Capital Advisors LP 971,639$25,622,1203.94%
M28 Capital Management LP 121,200$3,196,0443.66%
VIKING GLOBAL INVESTORS LP 25,120,991$662,440,5332.69%
BOONE CAPITAL MANAGEMENT LLC 313,381$8,263,8572.61%
Fernwood Investment Management, LLC 235,620$6,213,2992.23%
SOUTHPORT MANAGEMENT, L.L.C. 15,000$395,5502.15%
View complete list of BRIDGEBIO PHARMA INC shareholders